DYNE THERAPEUTICS
Dyne Therapeutics is a developer of targeted therapies intended for serious muscle diseases.The company's therapies deliver nucleic acids and other molecules to skeletal, cardiac and smooth muscle with unprecedented precision, enabling patients to restore muscle strength and transform their lives.
DYNE THERAPEUTICS
Industry:
Biotechnology Health Care Medical Pharmaceutical
Founded:
2018-01-01
Address:
Cambridge, Massachusetts, United States
Country:
United States
Website Url:
http://www.dyne-tx.com
Total Employee:
11+
Status:
Active
Total Funding:
333 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress Content Delivery Network
Similar Organizations
Ribonexus
Ribonexus is a biotech specialized in the development of new therapies to combat cancer disease.
Capital Rx
Capital Rx is a healthtech platform that provides pharmacy benefit management solutions.
Cisiv
Cisiv is a developer of technology solutions for pharmaceutical companies.
Endeavor BioMedicines
Endeavor BioMedicines develops new treatments targeting the underlying causes of pulmonary fibrosis.
HAYA Therapeutics
HAYA Therapeutics is a biopharmaceutical company that specializes in treating heart failure diseases.
LUCA Science
LUCA Science develops innovative treatments intended for mitochondrial and related diseases.
Neuron23
Neuron23 is a developer of drugs intended to treat Parkinson's disease and Alzheimer's disease.
Orasis Pharmaceuticals
Orasis Pharmaceuticals develops a corrective eye drop to treat presbyopia as an alternative to reading glasses.
PolyActiva
PolyActiva develops products that enable drug release from medical devices.
Priothera
Priothera is developing the orally applied sphingosine 1 phosphate (S1P) receptor modulators for haematological malignancies.
Pyxis Oncology
Pyxis Oncology is a developer of antibody therapeutics intended to promote the body's immune response to cancer.
Sydnexis
Sydnexis is engaged in the development of a proprietary treatment for pediatric progressive myopia.
Syndesi Therapeutics
Syndesi Therapeutics develops a drug candidate for the treatment of consecutive cognitive disorders of various neurological conditions.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Logos Capital
Logos Capital investment in Series B - Dyne Therapeutics
Wellington Management
Wellington Management investment in Series B - Dyne Therapeutics
Vida Ventures
Vida Ventures investment in Series B - Dyne Therapeutics
Franklin Templeton Investments
Franklin Templeton Investments investment in Series B - Dyne Therapeutics
Surveyor Capital
Surveyor Capital investment in Series B - Dyne Therapeutics
Forbion Capital Partners
Forbion Capital Partners investment in Series B - Dyne Therapeutics
Atlas Venture
Atlas Venture investment in Series B - Dyne Therapeutics
MPM Capital
MPM Capital investment in Series B - Dyne Therapeutics
Atlas Venture
Atlas Venture investment in Series A - Dyne Therapeutics
MPM Capital
MPM Capital investment in Series A - Dyne Therapeutics
Key Employee Changes
| Date | New article |
|---|---|
| 2020-01-13 | Dyne Therapeutics Announces Appointment of Molly White as Vice President, Medical Communications and Advocacy |
Official Site Inspections
http://www.dyne-tx.com Semrush global rank: 2.41 M Semrush visits lastest month: 7.53 K
- Host name: 187.128.203.35.bc.googleusercontent.com
- IP address: 35.203.128.187
- Location: Mountain View United States
- Latitude: 37.4043
- Longitude: -122.0748
- Metro Code: 807
- Timezone: America/Los_Angeles
- Postal: 94043
More informations about "Dyne Therapeutics"
About Us - Dyne Therapeutics
Dyne was founded with a singular focus: to deliver life-transforming therapies for people living with serious muscle diseases. We are utilizing our proprietary FORCE™ platform to overcome …See details»
Dyne Therapeutics Announces CEO Transition
Mar 25, 2024 Dyne Therapeutics is a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven …See details»
dyne-tx.com - Whois.com
Whois Lookup for dyne-tx.com. Login Sign up My Account Logout; Domains. ... Not Available From Registry Registrant Name: Registration Private Registrant Organization: Domains By …See details»
Dyne Therapeutics - LinkedIn
Dyne Therapeutics is a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases.See details»
Investors & Media - Dyne Therapeutics, Inc.
Dyne Therapeutics is a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases.See details»
Dyne Therapeutics Announces CEO Transition - BioSpace
Mar 25, 2024 “I want to thank Josh for his leadership as Dyne transitioned from a research organization to a clinical-stage company. It’s remarkable what he and the team have achieved …See details»
Corporate Responsibility - Dyne Therapeutics
Dyne Therapeutics is a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases.See details»
Dyne Therapeutics Announces CEO Transition - Yahoo Finance
Mar 25, 2024 John Cox John Cox, President and CEO of Dyne Therapeutics - John Cox, Industry Leader with Global Experience in Rare Disease Commercialization, Joins Dyne as …See details»
Pipeline - Dyne Therapeutics
We are building a leading muscle disease company focused on advancing innovative, life-transforming therapies for genetically driven diseases. Our initial focus is on myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy …See details»
Press Releases | Dyne Therapeutics, Inc.
Aug 29, 2024 [email protected] 781.786.8230 781.786.8230 linkedin.com twitter.com facebook.com; Focused on muscle and. positioned for growth. Press Releases; Events and …See details»
Dyne Therapeutics (@Dyne_tx) / Twitter
Jan 2, 2019 Dr. Ashish Dugar, Chief Medical Affairs Officer at Dyne Therapeutics, presents on the ACHIEVE study and Dyne’s investigational medicine, DYNE-101. Q&A hosted by Molly …See details»
Dyne Therapeutics Announces CEO Transition | Markets Insider
Mar 25, 2024 - John Cox, Industry Leader with Global Experience in Rare Disease Commercialization, Joins Dyne as President and CEO -WALTHAM, Mass., March 25, ...See details»
Dyne Therapeutics Announces CEO Transition
Mar 25, 2024 Dyne Therapeutics is a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven …See details»
Dyne Therapeutics Announces CEO Transition
I want to thank Josh for his leadership as Dyne transitioned from a research organization to a clinical-stage company. It s remarkable what he and the team have achieved in such a short …See details»
Cultivating A Dynamic Culture Centered Around ... - Dyne …
Apr 24, 2023 In just a few short years, Dyne, a leading muscle disease company, has quickly advanced from a small research to a clinical-stage company, and later this year, we expect …See details»
Dyne Therapeutics Accelerates Programs in Facioscapulohumeral …
May 19, 2020 Dyne to evaluate therapies targeting genetic cause of FSHD under agreement with international research organization UMONS. ... Mass. For more information, please visit …See details»
Careers + Culture - Dyne Therapeutics
We are fearless innovators united by a shared mission: To bring transformative therapies to people living with serious muscle diseases. We pursue our goals with passion, determination, …See details»
Dyne Therapeutics Reports Third Quarter 2024 Financial Results …
Nov 12, 2024 Dyne Therapeutics is a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven …See details»
Dyne Therapeutics Reports Fourth Quarter and Full Year 2022 …
Mar 2, 2023 - Data Anticipated in the Second Half of 2023 from ACHIEVE Clinical Trial of DYNE-101 in DM1 and DELIVER Clinical Trial of DYNE-251 in DMD - WALTHAM, Mass., March 02, …See details»